FDA Clears AI Advance for Detecting Intracranial Hemorrhage on Non-Contrast CT
The AI-powered Heuron ICH software reportedly has an 86 percent sensitivity rate for diagnosing intracranial hemorrhage on computed tomography (CT) scans.
The Food and Drug Administration (FDA) has granted 510(k) clearance for Heuron ICH, an artificial intelligence (AI)-enabled software that may facilitate timely detection and triage of intracranial hemorrhages.
Through interpretation of non-contrast computed tomography (CT) scans, Heuron ICH offers an 86 percent sensitivity rate and an 88 percent specificity rate for intracranial hemorrhage, according to Heuron, the developer of Heuron ICH.
For diagnosing intracranial hemorrhages on non-contrast CT, the newly FDA-cleared Heuron ICH offers an 86 percent sensitivity rate and an 88 percent specificity rate. (Images courtesy of Adobe Stock.)
Heuron maintained that Heuron ICH facilitates rapid detection of intracranial hemorrhages and can diagnose minute hemorrhages that may evade radiologist detection.
The company noted that Heuron ICH is Heuron’s fifth AI software to garner FDA clearance.
"Securing this product approval marks a significant milestone, facilitating our swift penetration into the U.S. market,” noted Donghoon Shin, the CEO of Heuron. “Our commitment extends beyond this achievement as we endeavor to expand our portfolio of FDA-approved medical solutions. We are dedicated to optimizing the utilization of Heuron's diverse offerings within U.S. clinical environments, particularly for emergency patient care."
Study: AI-Generated ADC Maps from MRI More Than Double Specificity in Prostate Cancer Detection
June 5th 2025Emerging research showed that AI-generated ADC mapping from MRI led to significant increases in accuracy, PPV and specificity in comparison to conventional ADC mapping while achieving a 93 percent sensitivity for PCa.
Can AI Assessment of PET Imaging Predict Treatment Outcomes for Patients with Lymphoma?
June 2nd 2025The use of adjunctive AI software with pre-treatment PET imaging demonstrated over a fourfold higher likelihood of predicting progression-free survival (PFS) in patients being treated for lymphoma, according to a new meta-analysis.
Lunit Unveils Enhanced AI-Powered CXR Software Update
May 28th 2025The Lunit Insight CXR4 update reportedly offers new features such as current-prior comparison of chest X-rays (CXRs), acute bone fracture detection and a 99.5 percent negative predictive value (NPV) for identifying normal CXRs.
